It is important that pharmacists ensure safe chemotherapy implementation. In addition to inspecting chemotherapeutic prescriptions according to patient condition and drug-drug interactions, the management of chemotherapy-induced adverse eŠects and associated pharmaceutical intervention is one of the most important responsibilities of pharmacists in medical care teams. In May 2016, an oncology pharmacist was set responsible for the specialized, long-term, and successive pharmaceutical care, including instructions about appropriate use of medication at an outpatient chemotherapy center. We evaluated the eŠectiveness of the continuous pharmaceutical care. The number of medication counseling and associated pharmaceutical interventions increased with time. Speciˆcally, the number of pharmaceutical interventions (prescription questions and pharmaceutical proposals) was 745 (459 and 286, respectively) in the surveillance period, which signiˆcantly increased compared to that observed within the same duration before posting an oncology pharmacist. The adoption rate was approximately 70％ for prescription questions and 98％ for pharmaceutical proposals. We also found that approximately 70％ of the proposals attenuated the painful symptoms. Furthermore, approximately 60％ of all pharmaceutical interventions were established after the third visit; in particular, approximately 20％ of the pharmaceutical proposals were suggested after the sixth visit, indicating that continuous medication counseling results in an increase in pharmaceutical proposals. In conclusion, long-term and successive pharmaceutical care by oncology pharmacy specialists in outpatient chemotherapy contributes to a safe and less onerous chemotherapy implementation, as it has been highly adopted, is eŠective in many cases, and has been proven to be important for risk management in chemotherapy.
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